Compare ARCL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCL | NRXP |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 151.1M |
| IPO Year | 2025 | 2017 |
| Metric | ARCL | NRXP |
|---|---|---|
| Price | $10.01 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 34.9K | ★ 572.1K |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,507.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $1.65 |
| 52 Week High | $10.03 | $5.06 |
| Indicator | ARCL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 37.16 |
| Support Level | $9.96 | $1.68 |
| Resistance Level | $10.02 | $3.62 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 72.73 | 38.94 |
ARC Group Acquisition I Corp is a blank check company.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.